History

2012

  • AlzeCure Foundation was formed

2013

  • AlzeCure Foundation initiated research and development at the Karolinska Institutet Science Park in Huddinge, Stockholm

2016

  • AlzeCure Pharma AB was formed

2017

  • AlzeCure Pharma concluded Series A financing round of 70 MSEK

2018

  • AlzeCure Pharma concluded a Series B financing round of 40 MSEK in order to finance Phase I studies of ACD855
  • Preclinical tests of ACD855 prior to Phase I was completed in July
  • IMPD (application to start human studies) for ACD855 was submitted in October